18 BlackRock Veracyte Trades
BlackRock's position in Veracyte is currently worth $658M. That's 0.01% of their equity portfolio (959th largest holding). The investor owns 17.79% of the outstanding Veracyte stock. The first Veracyte trade was made in Q4 2020. Since then BlackRock bought shares thirteen more times and sold shares on four occasions. The stake costed the investor $460M, netting the investor a gain of 43% so far.
News about Veracyte Inc and BlackRock
Veracyte to Release Second Quarter 2024 Financial Results on August 6, 2024
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) announced today that it will release financial results for the second quarter of ...
Veracyte (VCYT) Stock Jumps 13.2%: Will It Continue to Soar?
Veracyte (VCYT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may n...
This Top Medical Stock is a #1 (Strong Buy): Why It Should Be on Your Radar
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Rank.
Wall Street Analysts See a 37.09% Upside in Veracyte (VCYT): Can the Stock Really Move This High?
The mean of analysts' price targets for Veracyte (VCYT) points to a 37.1% upside in the stock. While this highly sought-after metric has not proven reasonabl...